ESR1 and breast carcinoma: Numerous other mechanisms contribute to increased MDM2 expression and/or activity in breast cancer, such as ERα-expression, downregulation of p14ARF, TGF1-b1-expression, as well as, expression of MDMX isoforms (reviewed in [34]).